Wolfgang Miesbach: How Laboratory Strategies Must Evolve to Meet Expanding Haemophilia Therapies
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
”An inspiring morning at EAHAD 2026 in Dublin: Annette Bowyer’s talk ‘Monitoring factor treatment in 2026 and beyond’ highlighted how rapidly our laboratory strategies must evolve to keep pace with the expanding spectrum of haemophilia therapies:
Monitoring needs to be tailored to the molecule and treatment class – from SHL/EHL/UHL concentrates to FVIII mimetics, gene therapy and emerging non‑factor therapies.
One‑stage and chromogenic assays each have strengths and limitations; for some products, results can be systematically over‑ or underestimated, demanding product‑specific approaches and clear lab–clinic communication.
Global assays of haemostasis and specific monitoring of FVIII mimetics and anti‑TFPI therapies are becoming increasingly important, but still require harmonisation and standardisation.
With more subcutaneous and non‑replacement options, the frequency and goals of monitoring are changing – from traditional peak/trough levels to efficacy, safety, inhibitor risk and transgene expression over the long term.
For haemophilia centres, this means closer collaboration between clinicians and specialised laboratories, investment in assay validation, and updated protocols to ensure safe, effective and personalised care in the era of innovative therapies.”
Stay updated with Hemostasis Today.
-
Sep 5, 2026, 10:12Wolfgang Miesbach: Can Emicizumab Be Used During Breastfeeding?
-
Sep 5, 2026, 09:52Lorena Arranz: Shaping the Future of Hematology with EHA 2027
-
Sep 5, 2026, 07:35Anticoagulation and Contemporary Secondary Prevention of Thrombosis in Polycythemia Vera
-
Sep 5, 2026, 05:48Punit Mathur: From Leg Pain to Life-Threatening Pulmonary Embolism
-
Sep 5, 2026, 05:44Patrick Stonich: Identifying Missed Signs of Postoperative Pulmonary Embolism in Medical Record Reviews
-
Sep 5, 2026, 05:38Tom Van den Hoek: Warburg Effect Mimicking Refractory Shock in Cancer-Associated PE
-
Sep 5, 2026, 05:11Shinya Goto: Targeted Thrombolysis for High Risk Pulmonary Embolism
-
Sep 5, 2026, 04:56Opportunities for the Next Generation of Hematologists – American Society of Hematology
-
Sep 5, 2026, 04:51Samuel Nwokolo: The Bone Marrow Factory – Anatomy of Blood Production